Cogent Biosciences is a biotechnology company developing precision therapies for genetically defined diseases, with its lead program being bezuclastinib, a targeted tyrosine kinase inhibitor for systemic mastocytosis and gastrointestinal stromal tumors. The company is building an internal commercial organization to bring bezuclastinib to market in the United States and is advancing a pipeline of additional targeted therapies for other cancers and genetic diseases. Revenue will be generated from product sales and potential licensing arrangements, with royalty obligations owed to the licensor of its lead asset.